Bristol-Myers Squibb Co. should be able to forestall some investor concerns about lagging sales of its one-time leading PD-1 inhibitor Opdivo when third quarter results are released on 31 October with the surprise announcement 22 October of an important win in the critical first-line lung cancer setting for the combination of Opdivo plus Bristol’s CTLA-4 inhibitor Yervoy and chemotherapy.
It’s an oddly similar dynamic to the previous quarter, when positive results from the Phase III CheckMate-227 trial came out...